Image

Natural History of Thyroid Function Disorders

Natural History of Thyroid Function Disorders

Recruiting
6-98 years
All
Phase N/A

Powered by AI

Overview

Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves' Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas.

The main purpose of this study is to further understand the natural history, clinical presentation, and genetics of thyroid function disorders. Many of the tests performed are in the context of standard medical care that is offered to all patients with thyroid function disorders. In addition, blood and tissue samples may be taken for research and genetic studies.

Description

Patients with thyroid function abnormalities (hyperthyroidism, hypothyroidism) are studied and treated in this protocol. Patients undergo routine history and physical examination, standard endocrine blood and urine tests, a standard TRH test, thyroid nuclear medicine scans, thyroidal radioiodine (RAI) or technetium (99mTc) uptake measurements, as well as X-ray, computed tomography (CT) or magnetic resonance imaging (MRI) studies or other standard diagnostic procedures, as clinically indicated.

The goals of this study are:

  • 1. To understand the pathophysiology and various causes of thyroid function abnormalities (e.g., hyperthyroidism, hypothyroidism).
  • 2. To longitudinally follow the effects of standard therapies for patients with abnormal thyroid functions.
  • 3. To create a repository of clinical data and biospecimens for future research of thyroid disorders.

Our objective will be accomplished by obtaining clinical data and biospecimens during standard care procedures and tests performed on enrolled subjects being evaluated as an outpatient in the clinic or as an inpatient at the NIH Clinical Center.

Eligibility

  • INCLUSION CRITERIA:

The categories of subjects eligible to participate in this study include:

  1. Patients with known or suspected thyroid abnormalities (e.g. hypothyroidism, hyperthyroidism, extreme iodine deficiency, and inherited forms of hypothyroidism resulting from abnormalities in the expression of genes coding for the TSH- beta subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS.
  2. Patients with thyroid function test (TFT) abnormalities due to:
    • Non-thyroidal illness
    • Abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia or hypotriiodothyronemia.
    • Genetic deficiency of thyroxine-binding globulin (TBG).
    • Antibodies to mouse immunoglobulins leading to an artifactual elevation in the TSH ultrasensitive ("3rd generation") assay which may mimic "inappropriate" secretion of TSH.

Inclusion and exclusion criteria for each group of subjects are given below.

        Patients with known or suspected thyroid abnormalities will be eligible to p rticipate if
        the individual meets all of the following criteria:
          1. Stated willingness to comply with all study procedures and availability for the
             duration of the study.
          2. Male or female, aged 6 months+.
        Hyperthyroid states include but are not restricted to:
          1. Graves' disease (GD) thought to result from thyroid-stimulating immunoglobulins
             (TSIg's), a subclass of which also stimulate eye muscle and fatty tissue producing
             exophthalmos (Graves' ophthalmopathy), as well as the skin in the pretibial area
             causing pretibial myxedema (Graves' dermopathy);
          2. Subacute thyroiditis (SAT), a painful inflammation thought to result from viral
             infection with Coxsackie, as well as other viruses;
          3. Silent thyroiditis, a painless inflammation thought to result from autoimmune attack
             of thyrocytes by antimicrosomal antibodies directed against thyroid peroxidase (TPO),
             as well as antithyroglobulin(anti-Tg) antibodies;
          4. Single or multiple hyperfunctioning thyroid nodules of unknown etiology, probably
             resulting from the activation of certain thyroid oncogenes and/or growth factors, such
             as the thyrotropin (TSH) receptor (TSHR) and the a-subunit of the G protein (Ga);
          5. Iodide-induced hyperthyroidism of unknown etiology;
          6. Surreptitious administration of thyroid hormone (TH), usually present in patients with
             underlying psychiatric disease or occasionally related to patients with obesity and
             other eating disorders
          7. Trophoblastic neoplasms, thought to result from high levels of hCG secretion, which,
             because of its structural similarity to TSH, causes "spillover" of action at the TSHR
             level;
          8. "Inappropriate" secretion of TSH, which may be present either in patients with TSH-
             producing pituitary tumors (TSHomas) or from a non-neoplastic cause, i.e. pituitary
             resistance to the action of thyroid hormone (3,4).
        Hypothyroid states include but are not restricted to:
          1. Primary (or thyroidal) hypothyroidism, usually resulting from auto-antibodies to
             thyroid proteins, such as antimicrosomal antibodies to TPO usually associated with
             lymphocytic (Hashimoto's) thyroiditis (HT) or atrophic thyroiditis, or blocking
             antibodies to the TSHR, usually in the context of non-goitrous hypothyroidism;
          2. Secondary (or pituitary) hypothyroidism, usually resulting from tumors of the
             pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or
             prolactinomas;
          3. Tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the
             hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology
             or secondary to a pituitary tumor;
          4. Bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic
             hormones or secondary to pituitary tumors (and usually related to abnormal
             glycosylation patterns of the TSH molecule);
          5. Generalized resistance to thyroid hormone (RTH), a disease which has been shown to be
             due to abnormalities in the TH receptor, c-erbA-beta (or TR- beta).
        The above are the principal disorders under study, but we may also investigate other
        abnormalities, such as extreme iodine deficiency, and inherited forms of hypothyroidism
        resulting from abnormalities in the expression of genes coding for the TSH- beta subunit,
        Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS (among others).
        EXCLUSION CRITERIA:
        There are no exclusion criteria for subjects with known or suspected thyroid abnormalities.

Study details
    Hyperthyroidism
    Hypothyroidism
    Grave's Disease

NCT00001159

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

18 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.